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Abstract
Background: Inhibitor of DNA binding/Inhibitor of differentiation 4 (ID4) is a critical factor for cell proliferation
and differentiation in normal vertebrate development. ID4 has regulative functions for differentiation and growth
of the developing brain. The role of ID1, ID2 and ID3 are expected to be oncogenic due to their overexpression
in pancreatic cancer and colorectal adenocarcinomas, respectively. Aside from these findings, loss of ID3
expression was demonstrated in ovarian cancer. The aim of the present study was to reveal the factual role of
ID4 in carcinogenesis in more detail, since its role for the pathogenesis of human breast cancer has been discussed
controversially, assigning both oncogenic and tumour suppressive functions. 
Methods: ID4 promoter methylation, ID4 mRNA expression and ID4 protein expression were analysed in
primary human breast cancer specimens using methylation-specific PCR (MSP) (n=170), semiquantitative realtime
RT-PCR (n=46) and immunhistochemistry (n=3), respectively. In order to demonstrate a functional association
of ID4 promoter methylation with its gene silencing, we performed DNA demethylation analysis with four human
breast cell lines using MSP and semiquantitative realtime RT-PCR. In addition, we performed correlations of ID4
promoter methylation with ID4 mRNA and ID4 protein expression in matched samples of breast tumour and
corresponding normal tissue. We carried out statistical analyses in order to find correlations between ID4
promoter methylation and clinicopathological parameters. 
Results: Frequent ID4 promoter methylation was observed in primary breast cancer samples (69%, 117/170).
We found a tight correlation (P<0.0001) between ID4 promoter methylation and loss of ID4 expression in
primary breast cancer 3 specimens. Demethylating treatment with breast cancer cell lines was associated with
clear ID4 mRNA re-expression. Tumours with ID4 promoter methylation showed distinct loss of ID4 expression
on both transcription and protein level. Interestingly, ID4 promoter methylation was a factor for unfavourable
recurrence-free survival (P=0.036) and increased risk for lymph node metastasis (P=0.030).  
Conclusion: ID4 is indeed a novel tumour suppressor gene in normal human breast tissue and is epigenetically
silenced during cancer development, indicating increased risk for tumour relapse. Thus, ID4 methylation status
could serve as a prognostic biomarker in human breast cancer.
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ID4 is the most recently discovered member of the Inhib-
itor of DNA binding/Inhibitor of differentiation family of
transcription factors. ID proteins contain a helix-loop-
helix (HLH) domain enabling interaction with other basic
helix-loop-helix (bHLH)-proteins. Via hetero-dimerisa-
tion with those transcription factors, ID proteins act as
dominant negative inhibitors of gene transcription [1]. In
addition, ID proteins can also bind to some important
non-bHLH transcription factors such as the retinoblastoma
gene product (RB1) or the paired box (PAX)-proteins,
thereby regulating important pathways in cell prolifera-
tion and differentiation [2,3]. Furthermore ID4 was found
to be an important factor for the development of the nerv-
ous system. In this tissue, the ID4 gene is highly expressed
in migrating postmitotic neurons, in Purkinje cells, as well
as in the adult cerebellum. Since ID proteins regulate fun-
damental cellular processes, a link of ID dysregulation
with human carcinogenesis has been recently postulated.
ID1, ID2 and ID3 are overexpressed in several human
tumour entities, e.g. pancreatic cancer [4] and colorectal
adenocarcinomas [5]. In addition, ID3 showed decreased
expression levels in several tumour types such as ovarian
adenocarcinomas [6,7]. In contrast to the putative onco-
genic properties of ID1 and ID2, ID4 expression was
found to be decreased in a variety of human cancers [8].
Recently, it has become very evident that aberrant epige-
netic modifications such as promoter methylation play a
decisive role in the dysregulation of gene expression in
cancer [9]. Hypermethylation of CpG-rich regions (CpG
islands) in promoter sequences is an important mecha-
nism for the silencing of tumour suppressor genes such as
p16INKa, p15INK4b, p14ARF, death-associated protein kinase
(DAPK) and O-6-methylguanine-DNA methyltransferase
(MGMT) [10]. In breast cancer, a variety of critical genes
were shown to be inactivated by methylation e.g. BRCA1,
14-3-3σ, TIM3 ESR1, PGR and E-cadherin [11]. The ID4
promoter region contains also CpG islands which were
found to be hypermethylated in gastric adenocarcinomas
in association with gene silencing [12]. Several studies
reported a potential correlation between ID4 promoter
methylation and tumour initiation/progression, e.g. in
colorectal carcinoma [13], human leukaemia [14] and
prostate cancer [2]. In human breast tissue ID4 mRNA was
found to be constitutively expressed in normal mammary
epithelial cells, but suppressed in oestrogen receptor (ER)-
positive breast carcinomas and pre-neoplastic lesions
[15]. A human ribozyme library-based inverse genomics
approach revealed that ID4 may act as a negative regulator
of the common tumour suppressor gene BRCA1 [16,17].
Moreover, ID4 expression levels were found to be
decreased in BRCA1/ER-positive breast cancer specimens,
suggesting that ID4 participates in molecular events regu-
lating ER and BRCA1 expression [18]. Aside from these
expression data, a role of ID4 as a putative tumour sup-
pressor in human breast cancer development has been
discussed controversially and is uncertain yet. In contrast
to the common ID4 downregulation in several human
tumour entities, one study detected increased ID4 expres-
sion in rat mammary gland cells in conjunction with
increased weight, proliferation and invasiveness of these
tumours [19]. However, another study suggested that ID4
may act as tumour suppressor gene in a fraction of pri-
mary breast cancers, since aberrant hypermethylation of
the ID4 gene promoter in T1 tumours was associated with
an increased risk for lymph node metastasis [20]. In the
present study, we readdressed the role of ID4 promoter
methylation in human breast cancer development. To that
end we analysed a large cohort (n = 170) of cryoconserved
samples of breast cancer specimens, including all tumour
sizes and histological grades. Using in vitro DNA demeth-
ylation treatment [21] of human breast cancer cell lines
we wanted to determine whether ID4 promoter hyper-
methylation may affect ID4 mRNA transcription. Our
next aim was to demonstrate for the first time a correla-
tion between ID4 promoter methylation and loss of ID4
mRNA and protein expression in primary human breast
cancer specimens. Finally, we aimed to analyse statistical
correlations between clinicopathological patient charac-
teristics and ID4 methylation and expression data.
Methods
Patient samples
Breast tissue samples (n = 170) used for methylation and
mRNA expression analyses were obtained from patients
treated by primary surgery for breast cancer at the Depart-
ments of Gynaecology at the University Hospitals of
Aachen, Jena, Regensburg and Düsseldorf, Germany, with
institutional review board approval. All patients gave
informed consent to the study for retention and analysis
of their tissue for research purposes. Part of the tumour
material and macroscopically normal breast was snap-fro-
zen in liquid nitrogen after surgery. Hematoxylin and
eosin (H&E)-stained sections were prepared for assess-
ment of the percentage of tumour cells, only samples with
>70% tumour cells were selected. The normal breast tissue
used for standardisation contained approximately 40% of
epithelial cells. For patient characteristics see Table 1.
Cell lines
The human breast cell lines BT20, MDA-MB231, MCF7
and T47D used for this study were obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA) and cultured under recommended conditions.
DNA/RNA isolation of breast cancer cells
Frozen tissue samples were dissolved in lysis buffer for
subsequent DNA isolation using the blood and cell cul-
ture DNA kit (Qiagen, Hilden, Germany) or for RNA iso-Page 2 of 11
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according to the protocol supplied by the manufacturer.
Reverse Transcription PCR
Of the total RNA, 1 μg was reverse transcribed using the
Reverse Transcription System (Promega, Madison, WI,
USA). To improve transcription rate we mixed oligo-dT
and pdN(6)-Primers 1:2. For PCR, 1 μl cDNA was ampli-
fied using ID4, (For 5'-CGC TCA CTG CGC TCA ACA C-3'
Rev 5'-CTA ACT TCT GCT CTT CCC CC-3', product size
148 bp) and Glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH) (For 5'-GAA GGT GAA GGT CGG AGT CA-3'
Rev 5'-TGG ACT CCA CGA CGT ACT CA-3', product size
289 bp) primers. Reactions were initiated as "Hot Start"
PCR at 95°C for 5 min and held at 80°C before addition
of 1 unit of Taq DNA polymerase (Roche, Mannheim,
Germany). Cycle conditions applied for both genes were:
94°C for 5 min, 38 cycles of 95°C for 1 min, 58°C for 1
min, 72°C for 1 min and a final extension at 72°C for 10
min. PCR analyses were carried out in a PTC-200 cycler
(Bio-Rad, formerly MJ Research, Hercules, CA, USA). The
amplification products were analysed on a 2% agarose gel
containing ethidium bromide under UV-light.
Semi-quantitative realtime PCR
Semi-quantitative PCR was performed using the LightCy-
cler system together with the LightCycler DNA Master
SYBR Green I Kit (Roche, Mannheim, Germany) as previ-
ously described [22]. Reaction volumes of 20 μl consisted
of the following components: 3 mM MgCl2, 10 μM for-
ward primer, 10 μM reverse primer, 2 μl LightCycler DNA
Master SYBR Green I and 1 μl of cDNA as PCR template.
For primer sequences of GAPDH and ID4 amplification,
see Reverse Transcription PCR section. To assure maxi-
mum specificity of ID4 mRNA detection a touchdown
PCR program was designed (see additional file 1). Gene
expression was quantified by the comparative CT method,
normalising CT-values to the housekeeping gene GAPDH
and calculating relative expression values [23]. Post
amplification melting curve analyses were performed to
assure product specificity. Relative ID4 expression levels
were standardised in comparison to the expression level
Table 1: Clinicopathological parameters of 170 breast cancer specimens analysed in this study.
Variable Categorisation na analysable %
Clinicopathologic parameters:
Age at diagnosis: median 57 years (range 28–87)
<50 years 53 31.2
≥ 50 years 117 68.8
Tumour sizec
pT1 62 36.5
pT2-4 91 53.5
pT xb 17 10
Lymph node statusc
pN0 74 43.5
pN1-3 62 36.5
pN x 34 20
Histological grade
G1 14 8.2
G2 79 46.5
G3 61 35.9
G x 16 9.4
Histological type
invasive ductal 128 75.3
Invasive lobular 18 10.6
other 24 14.1
Oestrogen receptor status
negative (IRSd 0–2) 52 30.6
positive (IRS 3–12) 101 59.4
IRS x 17 10
Progesterone receptor status
negative (IRS 0–2) 57 33.5
positive (IRS 3–12) 96 56.5
IRS x 17 10
aOnly female patients with primary, unilateral, invasive breast cancer were included. bx status unknown. cAccording to TNM classification by Sobin 
and Wittekind [37]. d IRS= Immuno-reactive score according to Remmele and Stegner [38].Page 3 of 11
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ment accuracy, all reactions were performed in triplicates.
Bisulphite-modification and methylation-specific PCR
Bisulphite-modification and methylation-specific PCR
(MSP) were performed as previously described
[22,24,25]. Of the genomic DNA, 1 μg was bisulphite-
treated using the EZ DNA Methylation Kit™ (Zymo
Research, Orange, CA, USA) according to the manufac-
turer's specifications. For MSP, 1 μl of modified DNA was
amplified using MSP primers that specifically recognise
the unmethylated (U For 5'-GGT AGT TG GAT TTT TTG
TTT TTT AGT ATT-3' Rev 5'-AAC TAT ATT TAT AAA ACC
ATA CAC CCC A-3, product size 157 bp) or methylated
(M For 5'-TAG TCG GAT TTT TCG TTT TTT AGT ATC-3'
Rev 5'-CTA TAT TTA TAA AAC CGT ACG CCC CG-3',
product size 161 bp) ID4 promoter sequence after bisul-
phite conversion. DNA derived from human carcinoma
cell line MDA-MB231 was bisulphite-treated to serve as a
control for the unmethylated ID4 promoter sequence.
DNA derived from human mammary carcinoma cell line
BT20 was used as a positive control for methylated ID4
sequences as described elsewhere [20]. Amplification
products were visualised by UV-illumination on 3% low
range ultra agarose gel (Bio-Rad Laboratories, Hercules,
CA, USA) containing ethidium bromide.
5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA) 
treatment
Cells were plated at a density of 3 × 104 cells/cm2 in a 6-
well plate on day 0. The demethylating agent DAC [26]
(Sigma-Aldrich, Deisenheim, Germany) was added to a
final concentration of 1 μM in fresh medium on days 1, 2
and 3. Additionally, 300 nM TSA (Sigma-Aldrich) was
added on day 3. Cells were harvested on day 4 for RNA
and DNA extraction. Control cells were incubated without
the addition of DAC or TSA and fresh medium was sup-
plied on days 1, 2 and 3.
Immunhistochemistry (IHC)
Sections of three micrometers were dried for 30 min at
72°C, deparaffinised in xylene, rehydrated in a decreasing
ethanol series and subsequently boiled for 35 min in Tris-
EDTA buffer (pH 9.0) for antigen retrieval. Polyclonal ID4
rabbit anti-human antibody (Sc291, Santa Cruz, CA,
USA) was utilised in 1:150 dilution and sections were
incubated for 90 min. IHC was performed by using the
ChemMate Envision Kit (DAKO, Hamburg, Germany).
Sections were counterstained with Mayer's hematoxylin
and embedded in Entellan® mounting medium (EMS Dia-
tome, Fort Washington, PA, USA). Sections of normal and
tumorous colon tissues were used for positive controls as
described elsewhere [13] (for details, see additional file
2). The application of primary antibody to tissue sections
was omitted in negative controls.
Statistical analyses of clinicopathological patient data
Statistical analyses were carried out by using SPSS version
14.0 (SPSS, Chicago, IL). Differences were considered sta-
tistically significant when P-values were located below
0.05. The two-sided, non-parametric Dunn's-Multiple-
Comparison-Test was used in order to compare the delta
CT values of the realtime RT-PCR results of the breast can-
cer group with the normal breast group as well as the dif-
ferent methylation groups. Two-sided Log-rank tests were
performed in order to correlate RFS/OS with ID4 methyl-
ation and other clinicopathological parameters. A multi-
variate Cox-regression analysis was performed in order to
test the independent prognostic relevance of ID4 methyl-
ation. The limit for reverse selection procedures was P =
0.2. The proportionality assumption for all variables was
assessed with log-negative-log survival distribution func-
tions.
Results
ID4 methylation, expression and re-expression analysis of 
mammary cell lines
First, we established a methylation-specific PCR (MSP) for
the ID4 gene, using MSP primers which are complemen-
tary to the central CpG island of the ID4 promoter region
(Figure 1A). The designed MSP primers amplify the ID4
promoter sequence starting approximately 30 bp
upstream of the transcription start site (TSS). In order to
demonstrate that ID4 promoter methylation may be asso-
ciated with ID4 gene silencing, we performed demethyla-
tion analyses with four human breast cancer cell lines
(MDA-MB231, BT20, MCF7 and T47D). For this purpose,
these cell lines were treated with the demethylating agent
DAC and the histone deacetylase inhibitor TSA. ID4
expression was measured 72 h later by performing real-
time PCR (Figure 1B). We found that in all methylated cell
lines (BT20, MCF7, and T47D) ID4 mRNA expression was
restored after the treatment. The increase of ID4 expres-
sion after promoter demethylation was 119-fold in T47D
cells, 38-fold in MCF7 cells and 19-fold in BT20 breast
cancer cells. The unmethylated cell line MBA-MD231
showed just a marginal alteration of its ID4 mRNA levels.
ID4 promoter methylation in primary human breast cancer
Recently we have demonstrated that ID4 mRNA expres-
sion is downregulated in 78% (39/50) of human primary
breast carcinomas [27]. Umetani et al. had shown before
that promoter hypermethylation is implicated to be an
effective mechanism of ID4 inactivation in human breast
cancer, albeit this group only analysed small sized (T1)
breast tumours [20]. In order to determine the exact meth-
ylation frequency of the ID4 promoter in a clinical rele-
vant spectrum of human breast cancer we analysed
genomic DNA from 170 primary breast cancer patients by
MSP technology.Page 4 of 11
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(A) Illustration of the ID4 gene promoter region and of MSP primer topologyFigure 1
(A) Illustration of the ID4 gene promoter region and of MSP primer topology. Two CpG islands are located in the 
ID4 promoter region upstream of the transcription start site (TSS). Methylation-specific PCR (MSP) primers used for this study 
were positioned within the central CpG island (-615 until +139) near the TSS, detecting an amplicon indicated by the black 
box. The PCR product size of the unmethylated ID4 promoter sequence is 161 bp and similar in size to the product achieved 
with primers indicating methylated ID4 promoters (157 bp). The primers for the U reaction cover the bases -194 until -166 
and -60 until -33. The primers for the M reaction cover the bases -192 until -166 and -60 until -35. All positions are relative to 
the TSS. (B) In vitro demethylation analysis of the ID4 promoter in four human breast cancer cell lines. Cells were 
incubated with 5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA) for 72 h and 24 h, respectively. For each cell line, the 
methylation status and the fold change (FC) of ID4 mRNA re-expression are shown. All methylated cell lines (BT20, MCF7 and 
T47D) restored ID4 expression after demethylating treatment. MDA-MB231 remains unmethylated in the ID4 promoter and 
exhibits only a marginal increase of ID4 mRNA expression after DAC/TSA treatment. (C) ID4 promoter methylation 
analysis in primary human breast cancer (n = 170) using MSP technology. MSP results from nine representative 
patients (#) are shown. DNA bands in lanes labelled with U indicate PCR products amplified with primers recognising the 
unmethylated promoter sequence. DNA bands in lanes labelled with M represent products amplified with primers specific for 
methylated alleles. Human breast cancer cell lines BT20 and MDA-MB321 were used as positive controls for methylated and 
unmethylated ID4 promoter sequences, as described previously [20]. Water was used as non template control (NTC).
BMC Cancer 2008, 8:154 http://www.biomedcentral.com/1471-2407/8/154Representative results are shown in Figure 1C. In total ID4
promoter methylation was found in 68.9% (117/170) of
breast cancer specimens. Accordingly, 31.1% of the breast
cancer specimens (53/170) exhibited no ID4 promoter
methylation. Normal breast tissues (n = 13) were analysed
by MSP as well and did not exhibit any ID4 promoter
methylation (data not shown), indicating that this is a
tumour-specific process.
Correlation analyses between ID4 promoter methylation 
and ID4 expression in human breast cancer
Next, we wanted to analyse whether ID4 promoter meth-
ylation consequently led to silencing of the ID4 promoter
as measured by realtime PCR analysis of the gene tran-
script. For this purpose, a part of the same breast cancer
cohort (n = 46) used previously for methylation analysis
was re-assessed (Figure 2A). Compared to a normal breast
tissue standard (12 pooled normal breast tissues) loss of
ID4 mRNA expression in unmethylated breast cancer
specimens was marginal (median fold change = 1.3). In
contrast, methylated breast cancer specimens exhibited a
highly significant (P < 0.001) loss of ID4 expression
(median fold change = 12.3). Thus, these data clearly indi-
cate that ID4 promoter methylation is associated with ID4
gene silencing. The comparison of ID4 expression in
breast tumours versus normal breast tissues resulted in
82.6% downregulation in tumour samples by the fold
change two (FC 2) approach. In order to confirm that pro-
moter methylation also affects loss of ID4 protein, we per-
formed a parallel analysis of ID4 promoter methylation,
mRNA and protein expression in three matched samples
with normal breast tissue and corresponding tumour tis-
sue (Figure 3A, B, C). Breast cancer specimens (T) with
unmethylated ID4 promoter exhibited only a marginal
decline (FC = 1.1) in ID4 mRNA expression. In accord-
ance with the mRNA data, the abundance of ID4 protein
in the tumour was very similar to that found in the corre-
sponding normal tissue (N). Breast cancer specimens
exhibited strong ID4 mRNA downregulation (16-fold and
71-fold, respectively) in comparison to their correspond-
ing normal tissues depending on clear ID4 promoter
methylation. Note, that in these tumour tissues nearly
complete loss of ID4 protein expression was evident (Fig-
ure 3B, C).
Statistical analysis of clinicopathological patient data and 
patient survival
Finally, descriptive Fisher's exact tests were performed in
order to correlate ID4 methylation with clinicopathologi-
cal patient characteristics (Table 2). A hypermethylated
ID4 promoter was significantly associated with positive
lymph node status (P = 0.03) and loss of ID4 mRNA
expression (P < 0.001). No associations were found with
age at diagnosis, tumour size, histological grade/type and
oestrogen/progesterone receptor status. A comparison
(A) Correlation between ID4 expression and ID4 promoter methylation n human breast cancerFigure 2
(A) Correlation between ID4 expression and ID4 pro-
moter methylation in human breast cancer. Box plot 
analysis illustrating the loss of ID4 expression in relation to 
ID4 promoter methylation in primary human breast cancer. 
The Y axis indicates the factor of ID4 mRNA downregulation 
in breast cancer specimens (n = 46) relative to a normal 
breast standard (a pool of 12 normal breast tissue samples) 
as the fold change (FC) N/T. Unmethylated tumours exhib-
ited ID4 expression (median FC = 1.3) very similar to normal 
breast cells. In contrast, methylated breast cancer specimens 
displayed an increased loss of ID4 expression (median FC = 
12.3). Horizontal lines: group medians; boxes: 25–75% quar-
tiles; vertical lines: range, peak and minimum. (B) Kaplan-
Meier analysis of patients' recurrence-free survival 
(RFS) in relation to ID4 promoter methylation. Distri-
bution of time (months) and tumour-related death among 
115 breast cancer patients with positive (lower graph) or 
negative (upper graph) ID4 promoter methylation state is 
shown. Patients harbouring an ID4-methylated tumour have 
an estimated mean RFS time of 80 months (95% confidence 
interval: 67–93 months) compared with 101 months (95% 
confidence interval: 87–115 months) for patients without ID4 
tumour methylation. See text for details.Page 6 of 11
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(OS) and ID4 methylation status is shown in Table 3. We
found an increased risk for tumour recurrence in breast
cancer patients with ID4 promoter methylation (P =
0.036) compared to patients with lack of ID4 methylation
(Figure 2B). Estimation was accomplished by the method
of Kaplan-Meier. ID4 promoter methylation is considera-
bly associated with a low 10-years RFS rate (47%) while
patients without ID4 promoter methylation have a 10-
years RFS rate of 71%. Cox regression models including
factors possibly influencing RFS in relation to ID4 pro-
moter methylation, failed significance in confirming the
prognostic value of ID4 promoter methylation as an inde-
pendent marker, probably due to its close relation to pos-
itive lymph node status (data not shown).
Discussion
Previous studies have shown that the HLH transcription
factor ID4 is functionally associated with fundamental
processes such as differentiation, proliferation, apoptosis
and angiogenesis [3] via interaction with cell cycle factors
like RB1-protein or the PAX-proteins [28]. For this reason
it is not surprising that all ID family members have been
Correlation of ID4 promoter methylation with ID4 expression on both mRNA and protein levelFigure 3
Correlation of ID4 promoter methylation with ID4 expression on both mRNA and protein level. Coherence of 
ID4 promoter methylation and ID4 expression in three representative samples of primary breast cancer and corresponding 
normal tissue (matched pairs a, b, c). Normal tissues are labelled with N. Their corresponding tumours are labelled with T. For 
each sample, ID4 promoter methylation, ID4 mRNA expression and ID4 immunohistochemical staining are shown (original 
magnification: 400×). The Fold change (FC) of ID4 mRNA downregulation is calculated by the expression ratio of normal (N) 
and tumourous tissue (T) for each matched pair (a, b, c). Matched pair a: Unmethylated tumour showed very similar ID4 
mRNA and protein expression compared to the corresponding normal breast tissue. Matched pairs b and c: Methylated 
tumours exhibited explicit loss of ID4 mRNA and ID4 protein in comparison to the corresponding normal breast tissues (N). 
See text for details.Page 7 of 11
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entities [29].
Epigenetic inactivation of the ID4 gene through promoter
methylation has been shown for several human tumour
types such as gastric carcinoma [12], colorectal carcinoma
[13] and acute leukaemia [14]. In breast cancer the epige-
netic regulation of ID4 expression was demonstrated in
67% (16/24) of node positive tumours, although only
breast tumours of small size (T1 tumours) were analysed
in this study [20]. Thus, it was the aim of the present work
to analyse the role of ID4 promoter methylation in a clin-
ical relevant cohort of human breast cancer and further to
study this process in human cell lines. ID4 promoter
methylation is indeed associated with ID4 gene silencing
in human breast cancer cell lines as in vitro demethylation
experiments with DAC in three methylated breast cancer
cell lines restored abundant ID4 mRNA expression. These
cell line results represent the prerequisite for a putative
tumour suppressive role of ID4 promoter methylation in
human breast cancer. Up to now, epigenetic silencing of
ID4 has been demonstrated only for gastric adenocarci-
noma [12] and colorectal carcinoma cell lines [13]. In
addition, we could show that a high percentage of human
primary breast cancers (69%) exhibit hypermethylation
of the ID4 promoter. Furthermore, we could show that
ID4 promoter methylation in human breast cancer is sig-
nificantly associated with loss of ID4 mRNA expression,
this tight correlation again being a prerequisite for a puta-
tive tumour suppressive function of ID4 promoter meth-
ylation in human breast cancer. Our results demonstrate a
highly significant loss of ID4 mRNA in 83% of human
breast cancers. This incidence of ID4 expression loss is
very similar to the 78% of ID4 mRNA downregulation
measured previously by a cancer profiling array [27].
However, our findings are not in accordance with the
determined ID4 mRNA upregulation described for rat
breast carcinoma cells [19]. Further studies will have to
show, whether ID4 regulation in human and rat breast
carcinogenesis might differ.
Table 2: Clinicopathological parameters in relation to ID4 promoter methylation
Variable ID4 Methylation
na Positive Negative P-valued
Total 170 117 53
Clinicopathological parameters:
Age at diagnosis
<50 years 51 34 17 0.821
≥ 50 years 111 76 35
Tumour sizeb
pT1 62 24 44 0.247
pT2-4 91 27 7
Lymph node statusb
pN0 74 43 31 0.030
pN1-3 62 47 15
Histological grade
G1 14 10 4 0.944
G2 79 52 27
G3 61 42 19
Histological type
invasive ductal 129 87 42 0.940
invasive lobular 18 12 6
other 12 8 4
Oestrogen receptor status
negative (IRSc 0–2) 52 35 17 0.900
positive (IRS 3–12) 101 69 32
Progesterone receptor status
negative (IRS 0–2) 57 39 18 0.920
positive (IRS 3–12) 96 65 31
ID4 mRNA expression x-fold
FC<2 8 0 8 <0.001
FC≥2 38 31 7
a Only female patients with primary, unilateral, invasive breast cancer were included. Significant P- values are marked in bold face. bAccording to 
TNM classification by Sobin and Wittekind [37]. c IRS = Immuno-reactive score according to Remmele and Stegner [38]. dFisher's exact test. 
Significant P- values are marked in bold face.Page 8 of 11
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moter methylation represents an adverse prognostic fac-
tor. Breast cancer patients harbouring a methylated ID4
promoter were found to have a decreased mean RFS time
in comparison to patients without ID4 methylation in the
tumour, supporting the hypothesis that a functional ID4
gene indeed confers tumour suppressive functions to
human breast tissue. Thus, ID4 may have the opposite
function of ID1 and ID2, which are thought to have onco-
genic properties in human breast cancer cells [30,31].
Additionally, Perk et al. reported an increased ID1 expres-
sion in human bladder and prostate cancer [32]. Support-
ing a metastasis suppressing function of ID4, we found a
significant positive correlation between ID4 promoter
methylation and lymph node metastasis in our large
cohort (n = 170) of breast cancer patients. This correlation
was also suggested for the cohort of T1 tumours in the
study of Umetani et al. [20]. No further correlations
between ID4 methylation and other clinicopathological
parameters were found. To our knowledge, this is the first
study presenting a distinct loss of ID4 protein expression
and ID4 mRNA downregulation associated with ID4 pro-
moter hypermethylation in human breast cancer. The loss
of protein expression, which modulates the activity of its
downstream targets, is an important milestone for the val-
idation of ID4 as a novel TSG in human breast cancer. Up
to now loss of the ID4 protein expression was observed in
sporadic breast adenocarcinomas [33] and colorectal car-
cinomas [13].
However, in these studies correlations between ID4 meth-
ylation and ID4 transcription were not determined. In
conclusion, our data show that ID4 is a potential tumour
suppressor gene in breast cancer that becomes epigeneti-
cally inactivated during cancer development owing to
aberrant promoter methylation. Our investigations form a
basis for further functional analyses in order to light up
the importance of ID4 for the progression and metastasis
of human breast cancer. The inactivation of tumour sup-
pressor genes through promoter methylation offers new
opportunities to identify novel DNA biomarkers in
human cancer diseases that may also represent targets for
improved future therapies [34,35]. DNA methylation
marker panels promise early detection, risk assessment,
chemoprediction and monitoring for disease recurrence
in combination with a minimally/non-invasive detection
in the blood stream or from archived tissue specimens
[36].
Table 3: Univariate analysis of clinicopathological parameters influencing recurrence-free survival (RFS) and overall survival (OS)
Variable RFS OS
na events P-valued n events P-value
Clinicopathological factors:
Tumour sizeb
pT1 44 14 0.142 45 7 0.396
pT2-4 77 35 79 16
Lymph node statusb
pN0 55 11 0.021 54 6 0.033
pN1-3 59 24 59 15
Histological grade
G1 11 3 0.018 10 1 0.019
G2 60 15 58 7
G3 60 30 54 17
Histological type
invasive ductal 107 33 0.006 106 23 0.877
invasive lobular 18 9 18 2
other 9 7 9 2
Oestrogen receptor status
negative (IRSc 0–2) 46 15 0.701 45 12 0.027
positive (IRS 3–12) 82 32 82 14
Progesterone receptor status
negative (IRSc 0–2) 43 18 0.240 43 11 0.059
positive (IRS 3–12) 85 29 84 15
ID4 promoter methylation
negative 39 8 0.036 39 5 0.169
positive 76 28 75 16
aOnly female patients with primary, unilateral, invasive breast cancer were included. bAccording to TNM classification by Sobin and Wittekind [37]. 
c IRS = Immuno-reactive score according to Remmele and Stegner [38]. dFisher's exact test. Significant P-values are marked in bold face.Page 9 of 11
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In summary, our analyses regarding aberrant ID4 pro-
moter methylation and differential ID4 expression on
both mRNA and protein level lead to the following con-
clusions: ID4 is indeed a tumour suppressor gene in nor-
mal breast tissue, which undergoes epigenetical silencing
during breast tumour development. The methylation sta-
tus of ID4 predicts early tumour relapse and could serve as
a prognostic biomarker in human breast cancer.
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